Excluding full year Elevate and integration costs of $71,000,000 our CARES Act repayment of $66,000,000 and employee retention credits Received a $24,000,000 normalized free cash flow was $303,000,000 in 2023. We repurchased 2,700,000 shares of common stock in the 4th quarter at an average price of $40.82 per share For a total cost of $110,000,000 for the full year, we repurchased 3,300,000 shares for $137,100,000 excluding excise taxes, and reduced our share count by 5%. Also, subsequent to the year end, our Board approved $150,000,000 expansion of our share repurchase authorization. The total current authorization is now $210,000,000 Interest expense was $20,500,000 up $4,500,000 from the prior year period. Now let's move on to the full year fiscal As shown on Slide 10, as Scott mentioned, our view for 2024 is consistent with the comments we made on the Q3 earnings call.